Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Teva
US Army
Moodys
Cantor Fitzgerald
McKinsey
Deloitte
Johnson and Johnson
Citi

Generated: May 24, 2018

DrugPatentWatch Database Preview

NEGGRAM Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Neggram, and when can generic versions of Neggram launch?

Neggram is a drug marketed by Sanofi Aventis Us and is included in two NDAs.

The generic ingredient in NEGGRAM is nalidixic acid. There are two drug master file entries for this compound. Additional details are available on the nalidixic acid profile page.
Summary for NEGGRAM
Drug patent expirations by year for NEGGRAM
Medical Subject Heading (MeSH) Categories for NEGGRAM
Synonyms for NEGGRAM
1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure
1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]
1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid
1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
1-Ethyl-1,8-naphthyridine-3-carboxilic acid
1-Ethyl-1,8-naphthyridine-3-carboxylic acid
1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-ca rboxylic acid
1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid
1-Ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid
1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naph thyridine-3-carboxylic acid
1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
1-ethyl-7-methyl-4-oxohydropyridino[2,3-b]pyridine-3-carboxylic acid
1, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-
1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid
1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-
1,8-Naphthyridine-3-carboxylicacid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-
3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one
3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one
3374-05-8 (hydrochloride salt, anhydrous)
389-08-2
389N082
3B91HWA56M
5-25-07-00384 (Beilstein Handbook Reference)
AB0013282
AB2000553
AC1L1I4P
AC1Q310A
Acid, Nalidixic
Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico
Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]
Acide nalidixico
Acide nalidixico [Italian]
Acide nalidixique
Acide nalidixique [French]
Acide nalidixique [INN-French]
Acido nalidissico
Acido nalidissico [DCIT]
Acido nalidixico
Acido nalidixico [INN-Spanish]
Acidum nalidixicum
Acidum nalidixicum [INN-Latin]
AK163550
AKOS000120074
ALBB-021275
AN-23434
ANW-42195
AS-13289
BB 0242389
BB_NC-2103
BBL012279
BDBM21691
Betaxina
BIDD:GT0529
BPBio1_000125
BRD-K47886988-323-03-0
BRN 0750515
BSPBio_000113
BSPBio_001889
C05079
CAS-389-08-2
CCG-39298
CCRIS 2365
CHEBI:100147
CHEMBL5
CPD000058264
CS-2493
CTK1C2660
Cybis
D00183
D07JGT
DB00779
DivK1c_000058
Dixiben
Dixinal
DR000512
DSSTox_CID_912
DSSTox_GSID_20912
DSSTox_RID_75859
DTXSID3020912
EINECS 206-864-7
Eucisten
Eucistin
F0850-6751
FT-0603390
H816
HE340309
HMS1921G10
HMS2092K04
HMS2232H24
HMS3259O13
HMS3374G11
HMS3656K05
HMS500C20
HMS561K17
HSDB 3241
HY-B0398
I14-18919
IDI1_000058
InChI=1/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17
Innoxalomn
Innoxalon
Jicsron
K-8443
KBio1_000058
KBio2_001398
KBio2_003966
KBio2_006534
KBio3_001109
KBioGR_001333
KBioSS_001398
KS-00000XTB
Kusnarin
Lopac0_000837
LS-72
Maybridge1_007101
MCULE-6808033849
MFCD00006884
MHWLWQUZZRMNGJ-UHFFFAOYSA-N
MLS000028504
MLS001148578
MLS002303041
MLS004820190
MLS006011875
MolPort-001-769-233
N-1200
N-benzyl-4-[(5-cyclobutyl-1,2,4-oxadiazol-3-yl)methyl]-N-ethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-6-sulfonamide
N0490
naladixic acid
Naldixic acid
Nalidic acid
Nalidicron
Nalidixan
Nalidixane
Nalidixate
NALIDIXATE SODIUM
Nalidixic
nalidixic acid
Nalidixic acid (JP15/USP/INN)
Nalidixic acid (JP17/USP/INN)
Nalidixic acid (NegGram)
Nalidixic acid [USAN:INN:BAN:JAN]
Nalidixic acid USP27
Nalidixic acid, >=98%
Nalidixic acid, analytical standard
Nalidixic acid, Antibiotic for Culture Media Use Only
Nalidixic acid, European Pharmacopoeia (EP) Reference Standard
Nalidixic acid, meets USP testing specifications
Nalidixic acid, United States Pharmacopeia (USP) Reference Standard
Nalidixin
Nalidixinic acid
Nalidixinsaure
Nalitucsan
Nalix
Nalurin
Narigix
Naxuril
NC00494
NCGC00018181-01
NCGC00018181-02
NCGC00018181-03
NCGC00018181-04
NCGC00018181-05
NCGC00018181-06
NCGC00018181-07
NCGC00018181-08
NCGC00018181-09
NCGC00018181-10
NCGC00018181-12
NCGC00018181-13
NCGC00021730-03
NCGC00021730-04
NCGC00021730-05
NCGC00021730-06
NCGC00021730-07
NCGC00256581-01
NCGC00259028-01
NCI-C56199
NCI60_041807
NCIOpen2_004342
NegGram (TN)
NegGram;Nevigramon;Nalidixin;Uronidix
Negram
Nevigramon
Nicelate
NINDS_000058
Nogram
NSC-757432
NSC-82174
NSC757432
NSC82174
Opera_ID_1064
Oprea1_010545
Pharmakon1600-01500756
Poleon
Prestwick0_000187
Prestwick1_000187
Prestwick2_000187
Prestwick3_000187
RTR-015647
S2328
SAM002554914
SBB002146
SBI-0050814.P003
SC-18641
SCHEMBL21736
Sicmylon
SMR000058264
SMR004703506
Sodium Nalidixic Acid, Anhydrous
Sodium Nalidixic Acid, Monohydrate
Sodium,Nalidixate
SPBio_001579
SPBio_002034
Specifen
Specifin
Spectrum_000918
SPECTRUM1500756
Spectrum2_001360
Spectrum3_000075
Spectrum4_000817
Spectrum5_001540
SR-01000003086-4
STK735579
Tox21_110835
Tox21_110835_1
Tox21_201477
Tox21_302754
TR-015647
Unaserus
UNII-3B91HWA56M
UPCMLD-DP129
UPCMLD-DP129:001
Uralgin
Uriben
Uriclar
Urisal
Urodixin
Uroman
Uroneg
Uronidix
Uropan
VU0239598-6
wil 18,320
WIN 18,320
Win 18320
WIN 183203
WIN-18320
WIN-18320 (TN)
Wintomylon
Wintomylon (TN)
Wintron
WLN: T66 BN EV JNJ B2 DVQ I1
Z256708444
ZERO/002632
ZINC57421

US Patents and Regulatory Information for NEGGRAM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us NEGGRAM nalidixic acid SUSPENSION;ORAL 017430-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us NEGGRAM nalidixic acid TABLET;ORAL 014214-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us NEGGRAM nalidixic acid TABLET;ORAL 014214-005 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us NEGGRAM nalidixic acid TABLET;ORAL 014214-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for NEGGRAM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us NEGGRAM nalidixic acid TABLET;ORAL 014214-005 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us NEGGRAM nalidixic acid SUSPENSION;ORAL 017430-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us NEGGRAM nalidixic acid TABLET;ORAL 014214-004 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us NEGGRAM nalidixic acid TABLET;ORAL 014214-002 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Julphar
Argus Health
Deloitte
Harvard Business School
Express Scripts
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.